Vaxcyte, Inc. PCVX
Vaxcyte, Inc. (Nasdaq: PCVX) is an infectious disease drug developer. Its lead program, VAX-31 (adult 31-valent pneumococcal conjugate vaccine), is in Phase 3 for prevention of invasive pneumococcal disease and pneumonia in adults 50+. Its next catalyst on record is VAX-31 adult: OPUS-2 and OPUS-3 Phase 3 data (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VAX-31 adult — OPUS-2 and OPUS-3 Phase 3 data (H1 2027). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VAX-31 adult (OPUS-1, OPUS-2, OPUS-3) | IPD / pneumococcal pneumonia in adults 50+ | vaccine | Phase 3 |
| VAX-31 infant | IPD in infants/children | vaccine | Phase 2 |
| VAX-24 infant | IPD in infants | vaccine | Phase 2 |
| VAX-A1 (Group A Strep) | Group A Streptococcus disease | vaccine | Phase 1 |
| VAX-XL | pneumococcal disease | vaccine | Pre-clinical |
| VAX-GI (Shigella) | dysentery / shigellosis | vaccine | Pre-clinical |
Recent results and decisions
- Oct 9, 2026n/a Vaxcyte completed concurrent offerings of $500 million convertible senior notes and 7,412,500 shares of common stock plus pre-funded warrants for 400,000 shares, raising combined net proceeds of approximately $959 million.
We estimate that the net proceeds to us from the Convertible Note Offering will be approximately $485.8 million and the net proceeds to us from the Common Stock Offering will be approximately $473.3 million.
Filing - Oct 5, 2026met OPUS-1 met all prespecified co-primary endpoints: noninferiority (OPA GMR LBCI >0.667) for all 28 shared serotypes vs PCV20/PCV21, superiority for 3 unique serotypes plus 20B, and immunobridging 18-49 vs 50-64; safety similar to PCV20/PCV21. Versus PCV21 alone, serotypes 3 and 12F missed LBCI >0.667 (17 of 19 met).
VAX-31 met all prespecified co-primary immunogenicity endpoints across all age groups studied in this pivotal Phase 3 trial, providing the clinical cornerstone for our planned Biologics License Application.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 infectious disease companies
- Gilead Sciences, Inc. GILD
- GSK plc GSK
- Moderna, Inc. MRNA
- Vir Biotechnology, Inc. VIR
- Novavax Inc NVAX
- Sinovac Biotech Ltd SVA
- CorMedix Inc. CRMD
- Valneva SE VALN
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.